Portage Biotech Inc (PRTG) Actualités

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd

WESTPORT, Conn., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. (“Portage” or the “Company”...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter

No impact at this time on the listing of the Company’s Ordinary Shares on NasdaqCompany intends to submit to...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024

WESTPORT, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ:...